Nanoscale drug delivery and hyperthermia: The materials design and preclinical and clinical testing of low temperature-sensitive liposomes used in combination with mild hyperthermia in the treatment of local cancer

Open Nanomedicine Journal

Volumn 3, Issue SPEC. ISSUE, 2011, Pages 38-64

  Landon, Chelsea D ^a   Park, Ji Young ^a   Needham, David ^b   Dewhirst, Mark W ^a,b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Duke University   (United States)

Author keywords

Cancer; Drug delivery; Hyperthermia; Low temperature sensitive liposomes

Indexed keywords

BORTEZOMIB; CISPLATIN; COPOLYMER; DACARBAZINE; DAUNORUBICIN; DENDRIMER; DEXAMETHASONE; DIPALMITOYLPHOSPHATIDYLCHOLINE; DISTEAROYLPHOSPHATIDYLCHOLINE; DITHIONITE; DOXORUBICIN; GADODIAMIDE; LANTHANIDE; LIPOSOME; LOW TEMPERATURE SENSITIVE LIPOSOME; MACROGOL; MACROGOL 2000; MANGANESE; MELPHALAN; METHOTREXATE; MITOMYCIN C; NANOPARTICLE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; PACLITAXEL; PLUMBAGIN; TEGAFUR; THALIDOMIDE; THERMODOX; TOPOTECAN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADD ON THERAPY; BLADDER CANCER; BREAST CANCER; CANCER ADJUVANT THERAPY; DRUG DELIVERY SYSTEM; DRUG DOSE ESCALATION; DRUG RELEASE; DRUG STRUCTURE; HUMAN; HYPERTHERMIC THERAPY; LIVER TUMOR; LOCAL CANCER; MATERIALS; MULTIPLE MYELOMA; NANOTECHNOLOGY; NEOPLASM; NONHUMAN; OVARY CANCER; OVARY CARCINOMA; PRIORITY JOURNAL; REVIEW;

EID: 80051916578     PISSN: None     EISSN: 18759335     Source Type: Journal    
DOI: None     Document Type: Review

References (216)

1. Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine 2006; 1: 297-315.
2. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science 2004; 303: 1818-22.
3. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005; 4: 145-60.
4. Jesorka A, Orwar O. Liposomes: technologies and analytical applications. Annu Rev Anal Chem (Palo Alto Calif) 2008; 1: 801- 32.
5. Needham D, Ponce A. In: Amiji MM, Ed. Nanotechnology for Cancer Therapy. CRC Press. 2006; pp. 677-719.
6. Koning GA, Eggermont AM, Lindner LH, ten Hagen TL. Hyperthermia and thermosensitive liposomes for improved delivery of chemotherapeutic drugs to solid tumors. Pharm Res 2010; 27: 1750-4.
7. Rahman A, Carmichael D, Harris M, Roh JK. Comparative pharmacokinetics of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes. Cancer Res 1986; 46: 2295-9.
8. Davis AJ, Tannock IF. Tumor physiology and resistance to chemotherapy: repopulation and drug penetration. Cancer Treat Res 2002; 112: 1-26.
9. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer 2006; 6: 583-92.
10. Papahadjopoulos D, Ed. Liposomes and their uses in biology and medicine. New York: Annals of the New York Academy of Sciences; 1978.
11. Allen TM. Liposomal drug formulations. Rationale for development and what we can expect for the future. Drugs 1998; 56: 747-56.
12. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 1999; 51: 691-743.
13. Torchilin VP. Targeted polymeric micelles for delivery of poorly soluble drugs. Cell Mol Life Sci 2004; 61: 2549-59.
14. Wang J, Mongayt D, Torchilin VP. Polymeric micelles for delivery of poorly soluble drugs: preparation and anticancer activity in vitro of paclitaxel incorporated into mixed micelles based on poly(ethylene glycol)-lipid conjugate and positively charged lipids. J Drug Target 2005; 13: 73-80.
15. Kabanov AV, Batrakova EV, Alakhov VY. Pluronic block copolymers as novel polymer therapeutics for drug and gene delivery. J Control Release 2002; 82: 189-212.
16. Rangel-Yagui CO, Pessoa A, Jr., Tavares LC. Micellar solubilization of drugs. J Pharm Pharm Sci 2005; 8: 147-65.
17. Discher BM, Won YY, Ege DS, et al. Polymersomes: tough vesicles made from diblock copolymers. Science 1999; 284: 1143- 6.
18. Dharap SS, Qiu B, Williams GC, Sinko P, Stein S, Minko T. Molecular targeting of drug delivery systems to ovarian cancer by BH3 and LHRH peptides. J Control Release 2003; 91: 61-73.
19. Kopecek J, Kopeckova P, Minko T, Lu ZR, Peterson CM. Water soluble polymers in tumor targeted delivery. J Control Release 2001; 74: 147-58.
20. Duncan R, Gac-Breton S, Keane R, et al. Polymer-drug conjugates, PDEPT and PELT: basic principles for design and transfer from the laboratory to clinic. J Control Release 2001; 74: 135-46.
21. Vasey PA, Kaye SB, Morrison R, et al. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin Cancer Res 1999; 5: 83-94.
22. Patri AK, Kukowska-Latallo JF, Baker JR, Jr. Targeted drug delivery with dendrimers: comparison of the release kinetics of covalently conjugated drug and non-covalent drug inclusion complex. Adv Drug Deliv Rev 2005; 57: 2203-14.
23. Choi Y, Baker JR, Jr. Targeting cancer cells with DNA-assembled dendrimers: a mix and match strategy for cancer. Cell Cycle 2005; 4: 669-71.
24. Fidler IJ, Raz A, Fogler WE, Kirsh R, Bugelski P, Poste G. Design of liposomes to improve delivery of macrophage-augmenting agents to alveolar macrophages. Cancer Res 1980; 40: 4460-6.
25. Poste G, Bucana C, Raz A, Bugelski P, Kirsh R, Fidler IJ. Analysis of the fate of systemically administered liposomes and implications for their use in drug delivery. Cancer Res 1982; 42: 1412-22.
26. Hunt CA, Rustum YM, Mayhew E, Papahadjopoulos D. Retention of cytosine arabinoside in mouse lung following intravenous administration in liposomes of different size. Drug Metab Dispos 1979; 7: 124-8.
27. Klibanov AL, Maruyama K, Torchilin VP, Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett 1990; 268: 235-7.
28. Needham D, Nunn RS. Elastic deformation and failure of lipid bilayer membranes containing cholesterol. Biophys J 1990; 58: 997-1009.
29. Hwang KJ, Luk KF, Beaumier PL. Hepatic uptake and degradation of unilamellar sphingomyelin/cholesterol liposomes: a kinetic study. Proc Natl Acad Sci U S A 1980; 77: 4030-4.
30. Szoka F, Jr., Papahadjopoulos D. Comparative properties and methods of preparation of lipid vesicles (liposomes). Annu Rev Biophys Bioeng 1980; 9: 467-508.
31. Allen TM, Hansen CB, de Menezes DEL. Pharmacokinetics of long-circulating liposomes. Adv Drug Deliv Rev 1995; 16: 267-84.
32. Dvorak HF, Nagy JA, Dvorak JT, Dvorak AM. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol 1988; 133: 95-109.
33. Dvorak HF, Orenstein NS, Carvalho AC, et al. Induction of a fibrin-gel investment: an early event in line 10 hepatocarcinoma growth mediated by tumor-secreted products. J Immunol 1979; 122: 166-74.
34. Nagy JA, Brown LF, Senger DR, et al. Pathogenesis of tumor stroma generation: a critical role for leaky blood vessels and fibrin deposition. Biochim Biophys Acta 1989; 948: 305-26.
35. Hong RL, Huang CJ, Tseng YL, et al. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial? Clin Cancer Res 1999; 5: 3645-52.
36. Hobbs SK, Monsky WL, Yuan F, et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci U S A 1998; 95: 4607-12.
37. Yuan F, Leunig M, Huang SK, Berk DA, Papahadjopoulos D, Jain RK. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res 1994; 54: 3352-6.
38. Wu NZ, Da D, Rudoll TL, Needham D, Whorton AR, Dewhirst MW. Increased microvascular permeability contributes to preferential accumulation of Stealth liposomes in tumor tissue. Cancer Res 1993; 53: 3765-70.
39. Wu NZ, Klitzman B, Rosner G, Needham D, Dewhirst MW. Measurement of material extravasation in microvascular networks using fluorescence video-microscopy. Microvasc Res 1993; 46: 231-53.
40. Kong G, Braun RD, Dewhirst MW. Hyperthermia enables tumorspecific nanoparticle delivery: effect of particle size. Cancer Res 2000; 60: 4440-5.
41. Dreher MR, Liu W, Michelich CR, Dewhirst MW, Yuan F, Chilkoti A. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J Natl Cancer Inst 2006; 98: 335-44.
42. Durand RE, Olive PL. Flow cytometry studies of intracellular adriamycin in single cells in vitro. Cancer Res 1981; 41: 3489-94.
43. Nguyen-Ngoc T, Vrignaud P, Robert J. Cellular pharmacokinetics of doxorubicin in cultured mouse sarcoma cells originating from autochthonous tumors. Oncology 1984; 41: 55-60.
44. El-Kareh AW, Secomb TW. A mathematical model for comparison of bolus injection, continuous infusion, and liposomal delivery of doxorubicin to tumor cells. Neoplasia 2000; 2: 325-38.
45. Ponce AM, Viglianti BL, Yu D, et al. Magnetic resonance imaging of temperature-sensitive liposome release: drug dose painting and antitumor effects. J Natl Cancer Inst 2007; 99: 53-63.
46. Kong G, Anyarambhatla G, Petros WP, et al. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release. Cancer Res 2000; 60: 6950-7.
47. ClinicalTrials.gov Phase 1/2 study of ThermoDox with approved hyperthermia in treatment of breast cancer recurrence at the chest wall (DIGNITY). [homepage on the internet]. Bethesda, MD: US National Institutes of Health; c1993-2010 [updated 2010 May 24; cited 2010 Aug 30]. Available from: http://www.clinicaltrials.gov/ ct2/show/NCT00826085?term=thermodox+rcw&rank=1
48. ClinicalTrials.gov A study of ThermoDox™ in combination with radiofrequency ablation (RFA) in primary and metastatic tumors of the liver. [homepage on the internet]. Bethesda, MD: US National Institutes of Health; c1993-2010 [updated 2009 Dec 16; cited 2010 Aug 30]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00441376?term=thermodox+RFA+liver&rank=1
49. ClinicalTrials.gov Phase 3 study of ThermoDox with radiofrequency ablation (RFA) in treatment of hepatocellular carcinoma (HCC). [homepage on the internet]. Bethesda, MD: US National Institutes of Health; c1993-2010 [updated 2010 Aug 10; cited 2010 Aug 30]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00617981?term=NCT00617981&rank=1
50. Storm FK. Clinical hyperthermia and chemotherapy. Radiol Clin North Am 1989; 27: 621-7.
51. Kong G, Braun RD, Dewhirst MW. Characterization of the effect of hyperthermia on nanoparticle extravasation from tumor vasculature. Cancer Res 2001; 61: 3027-32.
52. Matteucci ML, Anyarambhatla G, Rosner G, et al. Hyperthermia increases accumulation of technetium-99m-labeled liposomes in feline sarcomas. Clin Cancer Res 2000; 6: 3748-55.
53. Gaber MH, Wu NZ, Hong K, Huang SK, Dewhirst MW, Papahadjopoulos D. Thermosensitive liposomes: extravasation and release of contents in tumor microvascular networks. Int J Radiat Oncol Biol Phys 1996; 36: 1177-87.
54. Yatvin MB, Weinstein JN, Dennis WH, Blumenthal R. Design of liposomes for enhanced local release of drugs by hyperthermia. Science 1978; 202: 1290-3.
55. Yatvin MB, Muhlensiepen H, Porschen W, Weinstein JN, Feinendegen LE. Selective delivery of liposome-associated cisdichlorodiammineplatinum(II) by heat and its influence on tumor drug uptake and growth. Cancer Res 1981; 41: 1602-7.
56. Ben-Yosef R, Kapp DS. Persistent and/or late complications of combined radiation therapy and hyperthermia. Int J Hyperthermia 1992; 8: 733-45.
57. Dewhirst MW, Sim DA. The utility of thermal dose as a predictor of tumor and normal tissue responses to combined radiation and hyperthermia. Cancer Res 1984; 44: 4772s-80s.
58. Thrall DE, Prescott DM, Samulski TV, et al. Serious toxicity associated with annular microwave array induction of whole-body hyperthermia in normal dogs. Int J Hyperthermia 1992; 8: 23-32.
59. Overgaard J, Gonzalez D, Hulshof MC, et al. Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma: a multicentre randomized trial by the European Society for Hyperthermic Oncology. 1996. Int J Hyperthermia 2009; 25: 323-34.
60. Sherar M, Liu FF, Pintilie M, et al. Relationship between thermal dose and outcome in thermoradiotherapy treatments for superficial recurrences of breast cancer: data from a phase III trial. Int J Radiat Oncol Biol Phys 1997; 39: 371-80.
61. Leopold KA, Dewhirst M, Samulski T, et al. Relationships among tumor temperature, treatment time, and histopathological outcome using preoperative hyperthermia with radiation in soft tissue sarcomas. Int J Radiat Oncol Biol Phys 1992; 22: 989-98.
62. Milani V, Pazos M, Issels RD, et al. Radiochemotherapy in combination with regional hyperthermia in preirradiated patients with recurrent rectal cancer. Strahlenther Onkol 2008; 184: 163-8.
63. Wust P, Gellermann J, Harder C, et al. Rationale for using invasive thermometry for regional hyperthermia of pelvic tumors. Int J Radiat Oncol Biol Phys 1998; 41: 1129-37.
64. Goldberg SN, Gazelle GS, Mueller PR. Thermal ablation therapy for focal malignancy: a unified approach to underlying principles, techniques, and diagnostic imaging guidance. AJR Am J Roentgenol 2000; 174: 323-31.
65. Anyarambhatla GR, Needham D. Enhancement of the phase transition permeability of DPPC liposomes by incorporation of MPPC: a new temperature-sensitive liposome for use with mild hyperthermia. J Liposome Res 1999; 9: 491-506.
66. Needham D, Anyarambhatla G, Kong G, Dewhirst MW. A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. Cancer Res 2000; 60: 1197-201.
67. Lindner LH, Eichhorn ME, Eibl H, et al. Novel temperaturesensitive liposomes with prolonged circulation time. Clin Cancer Res 2004; 10: 2168-78.
68. Woo J, Chiu GN, Karlsson G, et al. Use of a passive equilibration methodology to encapsulate cisplatin into preformed thermosensitive liposomes. Int J Pharm 2008; 349: 38-46.
69. Maruyama K, Unezaki S, Takahashi N, Iwatsuru M. Enhanced delivery of doxorubicin to tumor by long-circulating thermosensitive liposomes and local hyperthermia. Biochim Biophys Acta 1993; 1149: 209-16.
70. Gaber MH, Hong K, Huang SK, Papahadjopoulos D. Thermosensitive sterically stabilized liposomes: formulation and in vitro studies on mechanism of doxorubicin release by bovine serum and human plasma. Pharm Res 1995; 12: 1407-16.
71. Wu NZ, Braun RD, Gaber MH, et al. Simultaneous measurement of liposome extravasation and content release in tumors. Microcirculation 1997; 4: 83-101.
72. Huang SK, Stauffer PR, Hong K, et al. Liposomes and hyperthermia in mice: increased tumor uptake and therapeutic efficacy of doxorubicin in sterically stabilized liposomes. Cancer Res 1994; 54: 2186-91.
73. Needham D, Dewhirst MW. The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors. Adv Drug Deliv Rev 2001; 53: 285-305.
74. Mills JK, Needham D. Lysolipid incorporation in dipalmitoylphosphatidylcholine bilayer membranes enhances the ion permeability and drug release rates at the membrane e phase transition. Biochim Biophys Acta 2005; 1716: 77-96.
75. Yarmolenko PS, Zhao Y, Landon C, et al. Comparative effects of thermosensitive doxorubicin-containing liposomes and hyperthermia in human and murine tumours. Int J Hyperthermia 2010; 26: 485-98.
76. Manzoor AA, Lindner LH, Park JY, et al. A new paradigm for drug delivery to tumors: the importance of triggered intravascular drug release from thermally-sensitive liposomes as a mechanism to enhance drug penetration distance. 2010; (In review).
77. Haest CW, de Gier J, van Es GA, Verkleij AJ, van Deenen LL. Fragility of the permeability barrier of Escherichia coli. Biochim Biophys Acta 1972; 288: 43-53.
78. Marsh D, Watts A, Knowles PF. Evidence for phase boundary lipid. Permeability of Tempo-choline into dimyristoylphosphatidylcholine vesicles at the phase transition. Biochemistry 1976; 15: 3570-8.
79. Mouritsen OG, Jorgensen K, Honger T. In: Disalvo EA, Simon SA, Eds. Permeability and stability of lipid bilayers. Boca Raton: CRC Press 1995; pp. 137-60.
80. Mouritsen OG, Zuckermann MJ. Model of interfacial melting. Phys Rev Lett 1987; 58: 389-92.
81. Papahadjopoulos D, Jacobson K, Nir S, Isac T. Phase transitions in phospholipid vesicles. Fluorescence polarization and permeability measurements concerning the effect of temperature and cholesterol. Biochim Biophys Acta 1973; 311: 330-48.
82. Mouritsen OG, Jorgensen K. Dynamical order and disorder in lipid bilayers. Chem Phys Lipids 1994; 73: 3-25.
83. Kenworthy AK, Hristova K, Needham D, McIntosh TJ. Range and magnitude of the steric pressure between bilayers containing phospholipids with covalently attached poly(ethylene glycol). Biophys J 1995; 68: 1921-36.
84. Hossann M, Wiggenhorn M, Schwerdt A, et al. In vitro stability and content release properties of phosphatidylglyceroglycerol containing thermosensitive liposomes. Biochim Biophys Acta 2007; 1768: 2491-9.
85. Nicholas AR, Scott MJ, Kennedy NI, Jones MN. Effect of grafted polyethylene glycol (PEG) on the size, encapsulation efficiency and permeability of vesicles. Biochim Biophys Acta 2000; 1463: 167-78.
86. Wright AM. Drug loading and release from a thermally sensitive liposome. Department of Mechanical Engineering and Materials Science Doctoral Thesis. Durham: Duke University 2006.
87. Li L, ten Hagen TL, Schipper D, et al. Triggered content release from optimized stealth thermosensitive liposomes using mild hyperthermia. J Control Release 2010; 143: 274-9.
88. Needham D, Stoicheva N, Zhelev DV. Exchange of monooleoylphosphatidylcholine as monomer and micelle with membranes containing poly(ethylene glycol)-lipid. Biophys J 1997; 73: 2615-29.
89. Ickenstein LM. Triggered drug release from thermosemsitive liposomes. Division of Pharmarceutics and Biopharmaceutics Doctoral Thesis. Vancouver, Canada: University of British Columbia 2003.
90. Tristram-Nagle S, Wiener MC, Yang CP, Nagle JF. Kinetics of the subtransition in dipalmitoylphosphatidylcholine. Biochemistry 1987; 26: 4288-94.
91. Taylor KMG, Craig DQM. In: Torchilin VP, Weissig V, Eds. Liposomes: a practical approach. 2nd ed. Oxford, Oxford University Press 2003; pp. 79-103.
92. New RRC, Ed. Liposomes: a practical approach. Oxford: IRL Press; 1990.
93. Kim DH, Costello MJ, Duncan PB, Needham D. Mechanical properties and microstructure of polycrystalline phospholipids monolayer shells: novel solid microparticles. Langmuir 2003; 19: 8455-66.
94. Ickenstein LM, Arfvidsson MC, Needham D, Mayer LD, Edwards K. Disc formation in cholesterol-free liposomes during phase transition. Biochim Biophys Acta 2003; 1614: 135-8.
95. Mills JK. Triggered release of liposome contents: mechanism involved in membrane permeability and compromise. Department of Mechanical Engineering and Materials Science Doctoral Thesis. Durham: Duke University 2002.
96. Langner M, Hui SW. Dithionite penetration through phospholipids bilayers as a measure of defects in lipid molecular packing. Chem Phys Lipids 1993; 65: 23-30.
97. Allen TM, Chonn A. Large unilamellar liposomes with low uptake into the reticuloendothelial system. FEBS Lett 1987; 223: 42-6.
98. Allen TM, Hansen C, Rutledge J. Liposomes with prolonged circulation times: factors affecting uptake by reticuloendothelial and other tissues. Biochim Biophys Acta 1989; 981: 27-35.
99. Mayer LD, Tai LC, Bally MB, Mitilenes GN, Ginsberg RS, Cullis PR. Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients. Biochim Biophys Acta 1990; 1025: 143-51.
100. Dewhirst MW, Tso CY, Oliver R, Gustafson CS, Secomb TW, Gross JF. Morphologic and hemodynamic comparison of tumor and healing normal tissue microvasculature. Int J Radiat Oncol Biol Phys 1989; 17: 91-9.
101. Chen Q, Tong S, Dewhirst MW, Yuan F. Targeting tumor microvessels using doxorubicin encapsulated in a novel thermosensitive liposome. Mol Cancer Ther 2004; 3: 1311-7.
102. Banno B, Ickenstein LM, Chiu GN, et al. The functional roles of poly(ethylene glycol)-lipid and lysolipid in the drug retention and release from lysolipid-containing thermosensitive liposomes in vitro and in vivo. J Pharm Sci 2010; 99: 2295-308.
103. Needham D. Temperature-sensitive liposomal formulation. US patent 6200598, March 2001.
104. Needham D. Temperature-sensitive liposomal formulation. US patent 6726925, April 2004.
105. Celsion [homepage on the internet]. Columbia, MD: Celsion Corporation, Inc.; c2000-2010 [updated 2010 March 10; cited 2010 2010 Aug 8]. Available from: http//:www.celsion.com
106. Li X, Hirsh DJ, Cabral-Lilly D, et al. Doxorubicin physical state in solution and inside liposomes loaded via a pH gradient. Biochim Biophys Acta 1998; 1415: 23-40.
107. Bally MB, Cullis PR, Hope MJ, Madden TD, Mayer LD. Encapsulation of antineoplastic agents in liposomes. US patent 5077056, Dec 1991.
108. Barenholz Y, Amselem S. Liposome Technology. 2nd ed. Boca Raton: CRC Press 1993.
109. Barenolz Y, Haran G. Method of amphiphatic drug loading in liposomes by pH gradient. US patent 5192549, March 1993.
110. Evans E, Kwok R. Mechanical calorimetry of large dimyristoylphosphatidylcholine vesicles in the phase transition region. Biochemistry 1982; 21: 4874-9.
111. Needham D, Evans E. Structure and mechanical properties of giant lipid (DMPC) vesicle bilayers from 20 degrees C below to 10 degrees C above the liquid crystal-crystalline phase transition at 24 degrees C. Biochemistry 1988; 27: 8261-9.
112. Rand RP, Pangborn WA, Purdon AD, Tinker DO. Lysolecithin and cholesterol interact stoichiometrically forming bimolecular lamellar structures in the presence of excess water, of lysolecithin or cholesterol. Can J Biochem 1975; 53: 189-95.
113. Klopfenstein WE, de Kruyff B, Verkleij AJ, Demel RA, van Deenen LLM. Differential scanning calorimetry on mixtures of lecithin, lysolecithin and cholesterol. Chem Phys Lipids 1974; 13: 215-22.
114. Ramsammy LS, Brockerhoff H. Lysophosphatidylcholinecholesterol complex. J Biol Chem 1982; 257: 3570-4.
115. Ramsammy LS, Volwerk H, Lipton LC, Brockerhoff H. Association of cholesterol with lysophosphatidylcholine. Chem Phys Lipids 1983; 32: 83-9.
116. Zhelev DV. Material property characteristics for lipid bilayers containing lysolipid. Biophys J 1998; 75: 321-30.
117. Sandstrom MC, Ickenstein LM, Mayer LD, Edwards K. Effects of lipid segregation and lysolipid dissociation on drug release from thermosensitive liposomes. J Control Release 2005; 107: 131-42.
118. Zhelev DV, Stoicheva N, Scherrer P, Needham D. Interaction of synthetic HA2 influenza fusion peptide analog with model membranes. Biophys J 2001; 81: 285-304.
119. Zhelev DV, Needham D. Interactions of pH-sensitive peptides and polymers with lipid bilayers: Binding and membrane stability. In: Current Topics in Membranes. Edited by S. A. Simon and T. J. McInotosh. USA: Academic Press, 2002; vol. 52: pp. 437-64.
120. Gland JL, Somorjai GA. Low energy electron diffraction and work function studies of benzene, naphthalene and pyridine adsorbed on Pt(111) and Pt(100) single crystal surfaces. Surf Sci 1973; 38: 157- 86.
121. Leszczynski J, Zerner MC. Molecular structure and vibrational spectra of dithionite ion by ab initio calculations. Chem Phys Lett 1989; 159: 143-7.
122. Lindner LH, Hossann M, Vogeser M, et al. Dual role of hexadecylphosphocholine (miltefosine) in thermosensitive liposomes: active ingredient and mediator of drug release. J Control Release 2008; 125: 112-20.
123. Hayashi H, Kono K, Takagishi T. Temperature-dependent associating property of liposomes modified with a thermosensitive polymer. Bioconjug Chem 1998; 9: 382-9.
124. Kono K, Yoshino K, Takagishi T. Effect of poly(ethylene glycol) grafts on temperature-sensitivity of thermosensitive polymermodified liposomes. J Control Release 2002; 80: 321-32.
125. Paasonen L, Romberg B, Storm G, Yliperttula M, Urtti A, Hennink WE. Temperature-sensitive poly(N-(2-hydroxypropyl)methacrylamide mono/dilactate)-coated liposomes for triggered contents release. Bioconjug Chem 2007; 18: 2131-6.
126. Presant CA, Proffitt RT, Teplitz RL, Williams LE, Tin GW. Method of delivering micellular particles encapsulating chemotherapeutic agents to tumors in a body. US patent 5441745, Aug 1995.
127. Presant CA, Proffitt RT, Teplitz RL, Williams LE, Tin GW. Method of targeting a specific location in a body. US patent 5435989, July 1995.
128. Presant CA, Proffitt RT. Method of targeting tumors in humans. United States patent 5019369, May 1991.
129. Alberts DS, Muggia FM, Carmichael J, et al. Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials. Semin Oncol 2004; 31: 53-90.
130. Mrozek E, Rhoades CA, Allen J, Hade EM, Shapiro CL. Phase I Trial of liposomal encapsulated doxorubicin (Myocet; D-99) and weekly docetaxel in advanced breast cancer patients. Ann Oncol 2005; 16: 1087-93.
131. Gelmon KA, Tolcher A, Diab AR, et al. Phase I study of liposomal vincristine. J Clin Oncol 1999; 17: 697-705.
132. Sarris AH, Hagemeister F, Romaguera J, et al. Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial. Ann Oncol 2000; 11: 69-72.
133. Ryan CW, Fleming GF, Janisch L, Ratain MJ. A phase I study of liposomal doxorubicin (Doxil) with topotecan. Am J Clin Oncol 2000; 23: 297-300.
134. Skubitz KM. Phase II trial of pegylated-liposomal doxorubicin (Doxil) in sarcoma. Cancer Invest 2003; 21: 167-76.
135. Martin FJ. Methods for determining liposome bioequivalence. US patent 20100209348, Aug 2010.
136. Kaasgaard T, Andresen TL, Jensen SS, Holte RO, Jensen LT, Jorgensen K. Liposomes containing alkylated methotrexate analogues for phospholipase A(2) mediated tumor targeted drug delivery. Chem Phys Lipids 2009; 157: 94-103.
137. Andresen TL, Davidsen J, Begtrup M, Mouritsen OG, Jorgensen K. Enzymatic release of antitumor ether lipids by specific phospholipase A2 activation of liposome-forming prodrugs. J Med Chem 2004; 47: 1694-703.
138. Jorgensen K, Davidsen J, Mouritsen OG. Biophysical mechanisms of phospholipase A2 activation and their use in liposome-based drug delivery. FEBS Lett 2002; 531: 23-7.
139. Yuan F, Salehi HA, Boucher Y, Vasthare US, Tuma RF, Jain RK. Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows. Cancer Res 1994; 54: 4564-8.
140. Kleiter MM, Yu D, Mohammadian LA, et al. A tracer dose of technetium-99m-labeled liposomes can estimate the effect of hyperthermia on intratumoral doxil extravasation. Clin Cancer Res 2006; 12: 6800-7.
141. Weinstein JN, Magin RL, Yatvin MB, Zaharko DS. Liposomes and local hyperthermia: selective delivery of methotrexate to heated tumors. Science 1979; 204: 188-91.
142. Leal BZ, Meltz ML, Mohan N, Kuhn J, Prihoda TJ, Herman TS. Interaction of hyperthermia with Taxol in human MCF-7 breast adenocarcinoma cells. Int J Hyperthermia 1999; 15: 225-36.
143. Alberts DS, Peng YM, Chen HS, Moon TE, Cetas TC, Hoeschele JD. Therapeutic synergism of hyperthermia-cis-platinum in a mouse tumor model. J Natl Cancer Inst 1980; 65: 455-61.
144. Hahn GM. Potential for therapy of drugs and hyperthermia. Cancer Res 1979; 39: 2264-8.
145. Chen Q, Krol A, Wright A, Needham D, Dewhirst MW, Yuan F. Tumor microvascular permeability is a key determinant for antivascular effects of doxorubicin encapsulated in a temperature sensitive liposome. Int J Hyperthermia 2008; 24: 475-82.
146. Sharma D, Chelvi TP, Kaur J, Ralhan R. Thermosensitive liposomal taxol formulation: heat-mediated targeted drug delivery in murine melanoma. Melanoma Res 1998; 8: 240-4.
147. Chelvi PT, Jain SK, Ralhan R. Heat-mediated selective delivery of liposome-associated melphalan in murine melanoma. Melanoma Res 1995; 5: 321-6.
148. Chelvi TP, Jain SK, Ralhan R. Hyperthermia-mediated targeted delivery of thermosensitive liposome-encapsulated melphalan in murine tumors. Oncol Res 1995; 7: 393-8.
149. Zhu L, Huo Z, Wang L, Tong X, Xiao Y, Ni K. Targeted delivery of methotrexate to skeletal muscular tissue by thermosensitive magnetoliposomes. Int J Pharm 2009; 370: 136-43.
150. Tiwari SB, Pai RM, Udupa N. Temperature sensitive liposomes of plumbagin: characterization and in vivo evaluation in mice bearing melanoma B16F1. J Drug Target 2002; 10: 585-91.
151. Chelvi TP, Ralhan R. Designing of thermosensitive liposomes from natural lipids for multimodality cancer therapy. Int J Hyperthermia 1995; 11: 685-95.
152. Hosokawa T, Sami M, Kato Y, Hayakawa E. Alteration in the temperature-dependent content release property of thermosensitive liposomes in plasma. Chem Pharm Bull (Tokyo) 2003; 51: 1227- 32.
153. Yuyama Y, Tsujimoto M, Fujimoto Y, Oku N. Potential usage of thermosensitive liposomes for site-specific delivery of cytokines. Cancer Lett 2000; 155: 71-7.
154. Kong G, Dewhirst MW. Hyperthermia and liposomes. Int J Hyperthermia 1999; 15: 345-70.
155. Palmer GM, Boruta RJ, Viglianti BL, Lan L, Spasojevic I, Dewhirst MW. Non-invasive monitoring of intra-tumor drug concentration and therapeutic response using optical spectroscopy. J Control Release 2010; 142: 457-64.
156. Frederiksen LJ, Siemens DR, Heaton JP, Maxwell LR, Adams MA, Graham CH. Hypoxia induced resistance to doxorubicin in prostate cancer cells is inhibited by low concentrations of glyceryl trinitrate. J Urol 2003; 170: 1003-7.
157. Lindner LH, Reinl HM, Schlemmer M, Stahl R, Peller M. Paramagnetic thermosensitive liposomes for MR-thermometry. Int J Hyperthermia 2005; 21: 575-88.
158. Zhaowu Z, Xiaoli W, Yangde Z, Xingyan L, Weihua Z, Nianfeng L. Preparation and characterization of Tegafur magnetic thermosensitive liposomes. Pharm Dev Technol 2009; 14: 350 - 7.
159. Wang T, Hossann M, Reinl HM, et al. In vitro characterization of phosphatidylglyceroglycerol-based thermosensitive liposomes with encapsulated 1H MR T1-shortening gadodiamide. Contrast Media Mol Imaging 2008; 3: 19-26.
160. Peller M, Schwerdt A, Hossann M, et al. MR characterization of mild hyperthermia-induced gadodiamide release from thermosensitive liposomes in solid tumors. Invest Radiol 2008; 43: 877-92.
161. Terreno E, Delli Castelli D, Cabella C, et al. Paramagnetic liposomes as innovative contrast agents for magnetic resonance (MR) molecular imaging applications. Chem Biodivers 2008; 5: 1901-12.
162. Fossheim SL, Il'yasov KA, Hennig J, Bjornerud A. Thermosensitive paramagnetic liposomes for temperature control during MR imaging-guided hyperthermia: in vitro feasibility studies. Acad Radiol 2000; 7: 1107-15.
163. Langereis S, Keupp J, van Velthoven JL, et al. A temperaturesensitive liposomal 1H CEST and 19F contrast agent for MR image-guided drug delivery. J Am Chem Soc 2009; 131: 1380-1.
164. de Smet M, Langereis S, van den Bosch S, Grull H. Temperaturesensitive liposomes for doxorubicin delivery under MRI guidance. J Control Release 2010; 143: 120-7.
165. Viglianti BL, Abraham SA, Michelich CR, et al. In vivo monitoring of tissue pharmacokinetics of liposome/drug using MRI: illustration of targeted delivery. Magn Reson Med 2004; 51: 1153- 62.
166. Viglianti BL, Ponce AM, Michelich CR, et al. Chemodosimetry of in vivo tumor liposomal drug concentration using MRI. Magn Reson Med 2006; 56: 1011-8.
167. ClinicalTrials.gov [homepage on the internet]. Bethesda, MD: US National Institutes of Health; c1993-2010 [updated 2010 March; cited 2010 March 22]. Available from: www.ClinicalTrials.gov
168. ClinicalTrials.gov Thalidomide + Dexamethasone vs. DOXIL (Doxorubicin HCl Liposome Injection) + Thalidomide + Dexamethasone in patients with newly diagnosed multiple myeloma. [homepage on the internet]. Bethesda, MD: US National Institutes of Health; c1993-2010 [updated 2010 Oct 18; cited 2010 Nov 18]. Available from: http://www.clinicaltrials.gov/ct2/ show/study/NCT00097981
169. Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007; 25: 3892-901.
170. Gordon AN, Tonda M, Sun S, Rackoff W. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 2004; 95: 1-8.
171. Alberts DS, Liu PY, Wilczynski SP, et al. Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200). Gynecol Oncol 2008; 108: 90-4.
172. Northfelt DW, Dezube BJ, Thommes JA, et al. Pegylatedliposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol 1998; 16: 2445-51.
173. Garcia AA, Kempf RA, Rogers M, Muggia FM. A phase II study of Doxil (liposomal doxorubicin): lack of activity in poor prognosis soft tissue sarcomas. Ann Oncol 1998; 9: 1131-3.
174. Ellerhorst JA, Bedikian A, Ring S, Buzaid AC, Eton O, Legha SS. Phase II trial of doxil for patients with metastatic melanoma refractory to frontline therapy. Oncol Rep 1999; 6: 1097-9.
175. Israel VP, Garcia AA, Roman L, et al. Phase II study of liposomal doxorubicin in advanced gynecologic cancers. Gynecol Oncol 2000; 78: 143-7.
176. Garcia AA, Roman L, Muderspach L, et al. Phase I clinical trial of topotecan and pegylated liposomal doxorubicin. Cancer Invest 2005; 23: 665-70.
177. Iqbal S, Tsao-Wei DD, Quinn DI, et al. Phase I clinical trial of pegylated liposomal doxorubicin and docetaxel in patients with advanced solid tumors. Am J Clin Oncol 2010; 34: 27-31.
178. Vujaskovic Z, Kim DW, Jones E, et al. A phase I/II study of neoadjuvant liposomal doxorubicin, paclitaxel, and hyperthermia in locally advanced breast cancer. Int J Hyperthermia 2010; 26: 514- 21.
179. Kouloulias VE, Dardoufas CE, Kouvaris JR, et al. Liposomal doxorubicin in conjunction with reirradiation and local hyperthermia treatment in recurrent breast cancer: a phase I/II trial. Clin Cancer Res 2002; 8: 374-82.
180. ® and whole abdomen hyperthermia in patients with refractory ovarian cancer. Int J Hyperthermia 2005; 21: 333-47.
181. Hauck ML, LaRue SM, Petros WP, et al. Phase I trial of doxorubicin-containing low temperature sensitive liposomes in spontaneous canine tumors. Clin Cancer Res 2006; 12: 4004-10.
182. Susaneck SJ. Doxorubicin therapy in the dog. J Am Vet Med Assoc 1983; 182: 70-2.
183. Vail DM, Kravis LD, Cooley AJ, Chun R, MacEwen EG. Preclinical trial of doxorubicin entrapped in sterically stabilized liposomes in dogs with spontaneously arising malignant tumors. Cancer Chemother Pharmacol 1997; 39: 410-6.
184. Poon RT, Borys N. Lyso-thermosensitive liposomal doxorubicin: a novel approach to enhance efficacy of thermal ablation of liver cancer. Expert Opin Pharmacother 2009; 10: 333-43.
185. Thomas MB, Jaffe D, Choti MM, et al. Hepatocellular carcinoma: consensus recommendations of the national cancer institute clinical trials planning meeting. J Clin Oncol 2010; 28: 3994-4005.
186. Hirata Y, Nishiwaki H. The choroidal circulation assessed by lasertargeted angiography. Prog Retin Eye Res 2006; 25: 129-47.
187. Hirata Y, Nishiwaki H, Miura S, Ieki Y, Kiryu J, Honda Y. In vivo analysis of choroidal circulation by continuous laser-targeted angiography in the rat. Invest Ophthalmol Vis Sci 2003; 44: 3103-9.
188. Asrani S, Zou S, D'Anna S, Goldberg MF, Zeimer R. Noninvasive visualization of blood flow in the choriocapillaris of the rat. Invest Ophthalmol Vis Sci 1996; 37: 312-7.
189. Asrani S, Zeimer R. Feasibility of laser targeted photo-occlusion of ocular vessels. Br J Ophthalmol 1995; 79: 766-70.
190. Asrani S, Zou S, D'Anna S, et al. Feasibility of laser-targeted photoocclusion of the choriocapillary layer in rats. Invest Ophthalmol Vis Sci 1997; 38: 2702-10.
191. Ruel-Gariepy E, Shive M, Bichara A, et al. A thermosensitive chitosan-based hydrogel for the local delivery of paclitaxel. Eur J Pharm Biopharm 2004; 57: 53-63.
192. Mulik R, Kulkarni V, Murthy RS. Chitosan-based thermosensitive hydrogel containing liposomes for sustained delivery of cytarabine. Drug Dev Ind Pharm 2009; 35: 49-56.
193. Ruel-Gariepy E, Leclair G, Hildgen P, Gupta A, Leroux JC. Thermosensitive chitosan-based hydrogel containing liposomes for the delivery of hydrophilic molecules. J Control Release 2002; 82: 373-83.
194. Kapp DS. Site and disease selection for hyperthermia clinical trials. Int J Hyperthermia 1986; 2: 139-56.
195. Falk MH, Issels RD. Hyperthermia in oncology. Int J Hyperthermia 2001; 17: 1-18.
196. Paulides MM, Bakker JF, Neufeld E, et al. Winner of the New Investigator Award at the European Society of Hyperthermia Oncology Meeting 2007. The HYPERcollar: a novel applicator for hyperthermia in the head and neck. Int J Hyperthermia 2007; 23: 567-76.
197. Sneed PK, Stauffer PR, McDermott MW, et al. Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost +/- hyperthermia for glioblastoma multiforme. Int J Radiat Oncol Biol Phys 1998; 40: 287-95.
198. Fatehi D, van der Zee J, van der Wal E, Van Wieringen WN, Van Rhoon GC. Temperature data analysis for 22 patients with advanced cervical carcinoma treated in Rotterdam using radiotherapy, hyperthermia and chemotherapy: a reference point is needed. Int J Hyperthermia 2006; 22: 353-63.
199. Gellermann J, Hildebrandt B, Issels R, et al. Noninvasive magnetic resonance thermography of soft tissue sarcomas during regional hyperthermia: correlation with response and direct thermometry. Cancer 2006; 107: 1373-82.
200. Franckena M, Fatehi D, de Bruijne M, et al. Hyperthermia doseeffect relationship in 420 patients with cervical cancer treated with combined radiotherapy and hyperthermia. Eur J Cancer 2009; 45: 1969-78.
201. Paulides MM, Bakker JF, Linthorst M, et al. The clinical feasibility of deep hyperthermia treatment in the head and neck: new challenges for positioning and temperature measurement. Phys Med Biol 2010; 55: 2465-80.
202. Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005; 366: 2087-106.
203. Juang T, Neuman D, Schlorff J, Stauffer PR. Construction of a conformal water bolus vest applicator for hyperthermia treatment of superficial skin cancer. Conf Proc IEEE Eng Med Biol Soc 2004; 5: 3467-70.
204. Boesch CE, Meyer T, Waschke L, et al. Long-term outcome of hyperthermic isolated limb perfusion (HILP) in the treatment of locoregionally metastasised malignant melanoma of the extremities. Int J Hyperthermia 2010; 26: 16-20.
205. Issels RD, Lindner LH, Verweij J, et al. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localized high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol 2010; 11: 561-70.
206. Jones E, Alvarez Secord A, Prosnitz LR, et al. Intra-peritoneal cisplatin and whole abdomen hyperthermia for relapsed ovarian carcinoma. Int J Hyperthermia 2006; 22: 161-72.
207. Colombo R, Da Pozzo LF, Salonia A, et al. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J Clin Oncol 2003; 21: 4270-6.
208. Moskovitz B, Meyer G, Kravtzov A, et al. Thermo-chemotherapy for intermediate or high-risk recurrent superficial bladder cancer patients. Ann Oncol 2005; 16: 585-9.
209. Gofrit ON, Shapiro A, Pode D, et al. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer. Urology 2004; 63: 466-71.
210. Guthkelch AN, Carter LP, Cassady JR, et al. Treatment of malignant brain tumors with focused ultrasound hyperthermia and radiation: results of a phase I trial. J Neurooncol 1991; 10: 271-84.
211. Kennedy JE. High-intensity focused ultrasound in the treatment of solid tumours. Nat Rev 2005; 5: 321-7.
212. Dromi S, Frenkel V, Luk A, et al. Pulsed-high intensity focused ultrasound and low temperature-sensitive liposomes for enhanced targeted drug delivery and antitumor effect. Clin Cancer Res 2007; 13: 2722-7.
213. Kennedy JE, Ter Haar GR, Cranston D. High intensity focused ultrasound: surgery of the future? Br J Radiol 2003; 76: 590-9.
214. Babincova M, Cicmanec P, Altanerova V, Altaner C, Babinec P. AC-magnetic field controlled drug release from magnetoliposomes: design of a method for site-specific chemotherapy. Bioelectrochemistry 2002; 55: 17-9.
215. Puri A, Kramer-Marek G, Campbell-Massa R, et al. HER2-specific affibody-conjugated thermosensitive liposomes (Affisomes) for improved delivery of anticancer agents. J Liposome Res 2008; 18: 293-307.
216. ® in combination with focused heat for the treatment of solid tumors Columbia, MD: Celsion Corporation 2008.